Long-Term Reassurance and Practical Management of Continuous BTK Inhibition in CLL
| Long-Term Reassurance and Practical Management of Continuous BTK Inhibition in CLL This program explores evolving strategies in the management of chronic lymphocytic leukemia (CLL), with insights from Drs. Ian Flinn and Danielle Brander. The discussion focuses on the integration of BTK inhibitors and BCL2-targeted therapy, particularly zanubrutinib and venetoclax, highlighting their efficacy, safety, and practical application. |
|
|
Featured Video |
 |
| Long-Term Reassurance and Practical Management of Continuous BTK Inhibition in CLL Experts discuss the promising long-term results of zanubrutinib for high-risk CLL patients, emphasizing the importance of upfront biomarker testing. |
|